The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506

Gene expression profiling predicts clinical outcome of breast cancer

van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1

Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069

Multidrug resistance in cancer: role of ATP–dependent transporters

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198

The resurgence of platinum-based cancer chemotherapy

Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges

Bagratuni, T., Papadimou, A., Taouxi, K., Dimopoulos, M. A., & Kastritis, E. (2023) · Hemato · doi:10.3390/hemato4030021 · Cited by 3

Understanding DNA and PARP in Cancer: Tackling Inhibitor Resistance

Balachandran, H., Byran, G., Karri, V. V. S. R., Murugesan, S. K., & Rajagopal, K. (2025) · Drug Metabolism and Bioanalysis Letters · doi:10.2174/0118723128343916250212094926 · Cited by 3

Genetic screens in mice for genome integrity maintenance and cancer predisposition

Balmus, G., & McIntyre, R. E. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.10.010 · Cited by 3

Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort

Kinalis, S., Nielsen, F. C., Talman, M., Ejlertsen, B., & Rossing, M. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1398837 · Cited by 3

Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection

Shin, J., Lee, K. S., Yoh, K. A., Cho, H. J., Choi, M. K., Kim, S. H., Kim, Y. J., Chung, J.-H., Cho, S., Kim, K., et al. (2018) · Oncology · doi:10.1159/000488201 · Cited by 3

Rubimaillin decreases the viability of human ovarian cancer cells via mitochondria-dependent apoptosis

Si-wei, Z., Zhen, W., Zhi, Z., Hu, X., & Li, Y. (2019) · Cellular and Molecular Biology · doi:10.14715/cmb/2019.65.7.13 · Cited by 3

SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer.

Han, X., Wang, Z., Zhang, L., Shen, Y., Tan, Q., Sun, Y., Wang, J., Qian, X., Yang, H., & Shi, Y. (2021) · PubMed Central · Cited by 3

Association of immune‐related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma

Tsukamoto, Y., Kurogi, S., Fujishima, H., Shibata, T., Fumoto, S., Nishiki, K., Suzuki, K., Etoh, T., Shiraishi, N., Fuchino, T., et al. (2023) · Cancer Science · doi:10.1111/cas.15942 · Cited by 3

Can antibody–drug conjugates bypass multidrug resistance of cancer cells?

Firer, M. A., & Luboshits, G. (2015) · doi:10.4155/fseb2013.14.86 · Cited by 3

Screening of medicinal phytocompounds with structure-based approaches to target key hotspot residues in tyrosyl-DNA phosphodiesterase 1: augmenting sensitivity of cancer cells to topoisomerase I inhibitors

Suleman, M., Khan, A., Khan, S. U., Alissa, M., Alghamdi, S. A., Alghamdi, A. A., Alamro, A. A., & Crovella, S. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2490061 · Cited by 2

Scutebarbatine B Exerts Anti‐Breast Cancer Activity by Inducing Cell Cycle Arrest and Apoptosis Through Multiple Pathways

Niu, C., Li, R., Hao, X., Xiao, Q., Wang, F.-Z., & Fei, H. (2025) · Phytotherapy Research · doi:10.1002/ptr.70007 · Cited by 2

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma

Li, N., Liu, Y., Zhang, L., Guo, S., Wu, Z., Xu, Y., Yang, M., Kong, J., Che, Y., Shao, K., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016765 · Cited by 2

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial

Seefat, R. L., Vliek, S. B., de Jong, V. M. T., Balduzzi, S., Mandjes, I. A. M., Retèl, V. P., Eekhout, I., Delfos, M., Schot, M. E., Holtkamp, M., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00131-2 · Cited by 2

Dequalinium-Mediated Mitochondria-Targeting Drug Liposomes for the Treatment of Drug-Resistant Lung Cancer

Ying, X. (2021) · Biomaterial engineering · doi:10.1007/978-3-662-49320-5_26 · Cited by 2

Analysis of DNA Repair-Related Prognostic Function and Mechanism in Gastric Cancer

Wang, L., Lu, J., Song, Y., Bai, J., Sun, W., Yu, J., Cai, M., & Fu, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.897096 · Cited by 2

Cytofluorometric assessment of acute cell death responses driven by radiation therapy

Álvarez-Abril, B., Bloy, N., Galassi, C., Sato, A., Jiménez‐Cortegana, C., Klapp, V., Aretz, A., Guilbaud, E., Buqué, A., Galluzzi, L., et al. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.05.002 · Cited by 2

Quantitation of the ataxia‐telangiectasia‐mutated and Rad3‐related inhibitor elimusertib (BAY‐1895344) in human plasma using LC–MS/MS

Kiesel, B. F., Parise, R. A., Krishnamurthy, A., Gore, S. D., & Beumer, J. H. (2022) · Biomedical Chromatography · doi:10.1002/bmc.5455 · Cited by 2

GATA factor TRPS1, a new DNA repair protein, cooperates with reversible PARylation to promote chemoresistance in patients with breast cancer

Zhang, J., Chen, Y., Gong, X. Q., Yang, Y., Gu, Y., Huang, L., Fu, J., Zhao, M., Huang, Y.-H., Li, L., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107780 · Cited by 2

Longitudinal Study of Transcriptomic Changes Occurring over Six Weeks of CHOP Treatment in Canine Lymphoma Identifies Prognostic Subtypes

Mee, M. W., Faulkner, S., Wood, G. A., Woods, J. P., Bienzle, D., & Coomber, B. L. (2024) · Veterinary Sciences · doi:10.3390/vetsci11110540 · Cited by 2

DNA Double-Strand Break Repair in Tumorigenesis and Anticancer Treatment

Her, C. (2014) · Chemotherapy Open access · doi:10.4172/2167-7700.1000124 · Cited by 2

Systematic Protein Level Regulation via Degradation Machinery Induced by Genotoxic Drugs

Kume, K., Ishida, K., Ikeda, M., Takemoto, K., Shimura, T., Young, L., & Nishizuka, S. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00759 · Cited by 2

The discovery of novel sanjuanolide derivatives as chemotherapeutic agents targeting castration-resistant prostate cancer

Wang, G., Chen, X., Wang, N., Xiao, Y., Shu, S., Alsayed, A. M. M., Liu, L., Ma, Y., Liu, P., Zhang, Q., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104880 · Cited by 2

Genome Conformity of In Vitro Cultures of Date Palm

El-Sharabasy, S. F., Mahdy, E. M. B., & Ghazzawy, H. S. (2021) · Compendium of plant genomes · doi:10.1007/978-3-030-73746-7_4 · Cited by 2

How Oncogenic Viruses Exploit p62-Mediated Selective Autophagy for Cancer Development

Wang, L. (2021) · Annals of Immunology & Immunotherapy · doi:10.23880/aii-16000134 · Cited by 1

An emerging role of N-glycosylation in cancer chemoresistance

Sun, Y., Wu, T., & Gu, J. (2024) · Carbohydrate Research · doi:10.1016/j.carres.2024.109107 · Cited by 2

Addicted to PAR?

Altmeyer, M. (2012) · Cell Cycle · doi:10.4161/cc.22393 · Cited by 2

Applications of liposomes for overcoming cancer drug resistance

Hosseinpour-Moghadam, R., Taghizadeh, F., Goshtasbi, N., Merati, F., & Haeri, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00001-x · Cited by 1

SARS-CoV-2 N protein exerts antitumor effects in NSCLC by inducing DNA damage and augmenting chemotherapeutic sensitivity

Wang, X., Cao, F., Chen, D., Bai, Y., Cui, X., Luo, Z., Guo, Y., Tong, R., Wu, M., Huang, A., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-02771-9 · Cited by 1

Multi-omics reveals FAT10 as an immunometabolic survival factor rewiring global metabolism in cancer

Loh, J. Y., Ching, J., Kovalik, J.-P., Liu, S.-C., Lim, L., Chong, S. S., & Lee, C. G. L. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02513-4

Ultrasound-induced Activation of Tetravalent Platinum Polyglutamate Nanoprodrug Accelerated by Coumarin Derivatives

Kong, C.-Y., Luo, C.-W., Xu, Y., Shen, N., & Tang, Z. (2025) · Chinese Journal of Polymer Science · doi:10.1007/s10118-025-3469-5 · Cited by 1

DNA damage-driven cGAS-STING activation via a nuclear-targeted probe enables potent near-infrared theranostics in breast cancer

Liu, R., Tan, Y., Jiang, Y., Zheng, J., Ni, W., Lin, S., Lin, J., Chen, D., Lyu, P., He, Y., et al. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.01.054 · Cited by 1

BTAF1: a key regulator of DNA end resection and predictor of chemotherapy sensitivity in gastric cancer

Xie, J.-J., Lin, J.-L., Xiang, Z., Qu, C., Cai, X., Nie, R., Lin, P. L., Yin, Y., Duan, J., Xie, D., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01709-6 · Cited by 1

The sulfonamide anticancer agent indisulam enhances the chemosensitivity of gastric cancer cells by targeting FKBP8

Li, Y., Lu, C., Lu, J., Jiang, H., Li, D., Wang, Y., Xu, G., Wang, X., & Ma, J. (2026) · FEBS Journal · doi:10.1111/febs.70494 · Cited by 1

Effects of Cytotoxic Therapies on the Sperm Genome and Epigenome

Conflitti, A. C., Buonacquisto, A., Cicolani, G., Quaranta, F., Paoli, E. D., Chiano, S. D., Lombardo, F., & Paoli, D. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-18376-7_5 · Cited by 1

ZIM, a Norbornene Derived from 4-Aminoantipyrine, Induces DNA Damage and Cell Death but in Association Reduces the Effect of Commercial Chemotherapeutics

Oliveira, R. J., da Silveira, I. O. M. F., das Neves, S. C., Barbosa, B. M., Martins, A. C. F., Berno, C. R., Mohammad, J., Raj, H., de Araújo, F. H. S., Hortelan, C. R., et al. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00275 · Cited by 1

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

Verbeek, J. G. E., de Jong, V. M. T., Wijnja, H. M., Jager, A., Linn, S. C., Retèl, V. P., & van Harten, W. H. (2023) · BMC Cancer · doi:10.1186/s12885-022-10412-x · Cited by 1

Inhibitory function of CDK12i combined with WEE1i on castration-resistant prostate cancer cells in vitro and in vivo

Qin, Z., Liu, D., Zhang, Y., Chen, X., Zhu, X., Xu, S., Peng, B., Dong, S., Hou, D., Zhu, L., et al. (2023) · ONCOLOGIE · doi:10.1515/oncologie-2023-0233 · Cited by 1

In Silico and In Vitro Studies of Novel Azomethines on DNA Repair Genes in Gastric Cell Lines

Öztürk, A., Ağbektas, T., Huseynzada, A., Guliyev, R., Ganbarova, R., Hasanova, U., Taş, A., Erkan, S., Zontul, C., İnandıklıoğlu, N., et al. (2023) · Life · doi:10.3390/life13101982 · Cited by 1

Cell Cycle, DNA Damage Repair Systems, and Impact of Redox Regulation in Cancer

Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_8 · Cited by 1

Two Birds with a Stone: Molecular Cancer Therapy Targeting Signal Transduction and DNA Repair Pathways

Zucca, E., Crespan, E., Bertoletti, F., Kiššová, M., & Maga, G. (2013) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-1-4614-7070-0_9 · Cited by 1

Unraveling the DNA Damage Response Signaling Network Through RNA Interference Screening

von Stechow, L., van de Water, B., & Danen, E. H. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397862-2.00003-6 · Cited by 1

Dietary Factors May Influence the Clinical Outcome of Chemotherapy in Cancer Multidrug Resistance

Ullah, M. F., Bhat, S. H., & Abuduhier, F. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-21461-0_15 · Cited by 1

Targeting Cell Cycle Proteins in Brain Cancer

Ferry, I., Kuzan-Fischer, C. M., Ernoult, E., & Rutka, J. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00019-x · Cited by 1

Atlantis exploration: predictive biomarkers to immunotherapy response

Носов, А. К., Кротов, Н. Ф., & Беркут, М. В. (2021) · Cancer Urology · doi:10.17650/1726-9776-2021-17-1-167-177 · Cited by 2

Análisis del efecto quimiosensibilizador del resveratrol, mediante la inhibición de la vía de reparación del ADN por recombinación homóloga (RH), en líneas celulares de cáncer cérvico-uterino

Vizcarra, A. S. (2020) · doi:10.24275/uami.v692t6367 · Cited by 1

Molecular Mechanisms for Targeting Metastatic Cancer Cells and to Overcome or Prevent Chemotherapy ResistancePreprint

Eslami, M., Davarpanah, A., Rismanbaf, A., Taghizadeh‐Hesary, F., Dorgaleleh, S., Memarsadeghi, O., Nayernia, K., & Behnam, B. (2023) · Preprints.org · doi:10.20944/preprints202306.0602.v1 · Cited by 1

SYNTHETIC LETHALITY OF CDK INHIBITION AND DOXORUBICIN IN TRIPLE-NEGATIVE BREAST CANCER REQUIRES P53 INACTIVATION

Jabbour-Leung, N. A. (2015) · Digital Commons-TMC (Texas Medical Center)

Implications of BRCA1 mutations in basal-like breast cancer development and treatment

Gu, Y. (2015) · Työväentutkimus Vuosikirja

Building a map of the breast cancer proteome - Strategies to increase coverage

Cifani, P. (2013) · Lund University Publications (Lund University)

RAD51C IS A TUMOR SUPPRESSOR IN MAMMARY AND SEBACEOUS GLANDS

Tumiati, M. (2015) · Työväentutkimus Vuosikirja

Multimodal Nano-Systems for Cancer Diagnosis, Imaging, and Therapy

Singh, A., Oka, A., Pandya, P., & Amiji, M. M. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_13

Identification of synthetic cytotoxic interactions to improve the efficacy of DNA damaging therapeutic agents

Moshgabadi, N. (2014) · cIRcle (University of British Columbia) · doi:10.14288/1.0166852

Assessment of a novel Cu (II) complex as a potential anticancer agent

dos Santos, S. G. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.13140/rg.2.2.17462.86084

Abrupt transitions to tumor extinction: A phenotypic quasispecies modelPreprint

Josep Sardanyés, A., Martínez, R., Simó, C., & Solé, R. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/044644

ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth

Cao, J., Dai, X., Wan, L., Wang, H., Zhang, J., Goff, P. S., Sviderskaya, E. V., Xuan, Z., Xu, Z., Xu, X., et al. (2016)

Potential Therapeutic Effects of Natural Extracts in Multiple Myeloma

(2016) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1311

DNA Double-Strand Break Repair and Anti-Cancer Therapy

Xu, Y., & Her, C. (2014)

RXDX-107, A Dodecanol Alkyl Ester of Bendamustine, Demonstrates Greater Stability and Broad Antitumor Activity in Multiple Pre-Clinical Models of Solid Tumor

Martin, L. (2016) · Chemotherapy Open access · doi:10.4172/2167-7700.1000213

Characterisation of caspase-2 function in the DNA damage response and tumour suppression.

Puccini, J. (2014) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)

Searching the molecular mechanism by which p-cadherin expression confers resistance to DNA damage in normal and breast cancer cell lines

Lopes, F. S. M. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/g0bc-a794

An evaluation of the checkpoint kinase inhibitor V158411

Stephens, P. (2015)

ß-Amido Acid Functionalised Superparamagnetic Iron Oxide Nanoparticles as a Novel Carrier for Efficient Delivery of Doxorubicine

Ebrahimi, F., Karimi, M., Sereshti, H., & Yousefifar, M. (2017) · Journal of Chemical Research · doi:10.3184/174751917x14873588907602

Inhibition of the kinase Wee1 - Cytotoxic mechanisms and autoprotection by the tumor suppressor p53

Li, Y. (2017) · doi:10.53846/goediss-6554

Aplication of Gas Hydrates as an Alternativ Dehydration Methode

Lal, B. (2017) · Recent Advances in Petrochemical Science · doi:10.19080/rapsci.2017.02.555585

Dequalinium-Mediated Mitochondria-Targeting Drug Liposomes for the Treatment of Drug-Resistant Lung Cancer

Ying, X. (2018) · Springer Reference Technik · doi:10.1007/978-3-662-49231-4_26-1

HSATII RNA is induced via a non-canonical ATM-regulated DNA-damage response pathway and facilitates tumor cell proliferation and movementPreprint

Nogalski, M. T., & Shenk, T. E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.25.115238

Cancer drugs targeting DNA replication: Molecular strategies to enhance specificity and efficacy

Li, Y. (2020) · doi:10.53846/goediss-8088

Advance in Pancreatic Cancer Diagnosis and Therapy

Cai, X., Gao, J., Liu, Y., Wang, M., Ma, Q., Gong, A., Wang, D., & Zhu, H. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94413

Smart Gold-Polymer Nanostructures As Promising Drug Nanocarriers For Dual-Imaging Modality And Synergistic Chemo-Photothermal Therapy in Breast Cancer CellsPreprint

Azizi, M., Pakravan, A., Valizadeh, H., Rahbarghazi‬, R., Dianat‐Moghadam, H., Bani, F., Kahroba, H., Salehi, R., & Mehrmohammadi, M. (2021) · Research Square · doi:10.21203/rs.3.rs-982173/v1

Poly(amido-amine) dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance in cancer

Pan, J. (2020) · doi:10.17760/d20383641

High-Dose Chemotherapy with Stem Cell Rescue to Treat Stage III Homologous Deficient Breast Cancer: Factors Influencing Clinical ImplementationPreprint

Verbeek, J. G. E., de Jong, V. M. T., Wijnja, H. M., Jager, A., Linn, S. C., Retèl, V. P., & van Harten, W. H. (2022) · Research Square · doi:10.21203/rs.3.rs-1407927/v1

Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells

Kumar, S., Zeng, Z., Bagati, A., Tay, R. E., Sanz, L. A., Hartono, S. R., Ito, Y., Abderazzaq, F. O., Hatchi, E., Jiang, P., et al. (2023) · doi:10.1158/2159-8290.c.6549178.v1

Data from RAD51AP1 Loss Attenuates Colorectal Cancer Stem Cell Renewal and Sensitizes to Chemotherapy

Bridges, A. E., Ramachandran, S., Tamizhmani, K., Parwal, U., Lester, A., Rajpurohit, P., Morera, D. S., Hasanali, S. L., Arjunan, P., Jedeja, R. N., et al. (2023) · doi:10.1158/1541-7786.c.6545298.v1

Resistance of prostate cancer to topoisomerase inhibitors

Gomez, A. S., Hachem, S., & Poppiti, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00005-1

SMAC mimetics overcome apoptotic resistance in ovarian cancer through MSLN-TNF alpha axisPreprint

Coelho, R., Seashore-Ludlow, B., Schütz, S., Lombardo, F. C., Moussaud-Lamodière, E., Casanova, R., Ficek-Pascual, J., Labrosse, K. B., Hensler, M., Lopez-Nunez, M., et al. (2024) · bioRxiv · doi:10.1101/2024.01.24.576987

Additional file 6 of Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine

Tong, Z., Yan, C., Dong, Y., Yao, M., Zhang, H., Liu, L., Zheng, Y., Zhao, P., Wang, Y., Fang, W. J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12986298

Drugs targeting microRNAs that regulate DNA damage sensing and repair mechanisms: A computational drug discovery approachPreprint

Ravindranath, S. B., Vratin, S., Lakshmi, B. S., Ramirez, D., & Gomez-Mejiba, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.18.599590 · Cited by 1

High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers

Verbeek, J. G. E., Azarang, L., Pilli, L. E., de Jong, V. M. T., Jager, A., Linn, S. C., Retèl, V. P., & van Harten, W. H. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.40276

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study

van Ommen‐Nijhof, A., Steenbruggen, T. G., Wiersma, T., Balduzzi, S., Daletzakis, A., Holtkamp, M., Delfos, M., Schot, M. E., Beelen, K. J., Siemerink, E., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115083

Role of genetic mechanism in cancer

Chauhan, K., & Rana, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95258-3.00002-3

Durable Complete Remission of Metastatic Gastric Cancer Following Platinum-Based Chemotherapy: A Case Report

Pilch, W., Wojturska, W., & Potocki, P. M. (2024) · Cureus · doi:10.7759/cureus.76378

Statistical Analysis of Gene Variants for Homologous Recombination Pathways of DNA Repair leading to Cancer Susceptibility

Adiga, U. S., Jyoti, B., Reddemma, P. P., Augustine, A. A., & Vasishta, S. (2024) · International Journal of Statistics in Medical Research · doi:10.6000/1929-6029.2024.13.36

Establishment of in silico prediction of adjuvant chemotherapy response from active mitotic gene signature in non-small cell lung cancerPreprint

Kwon, E., Hwang, H. S., Chang, E., An, J., & Cha, H. (2025) · medRxiv · doi:10.1101/2025.03.14.25322930

Induction of Moderate DNA Damage Enhances Megakaryopoiesis and Platelet ProductionPreprint

Bekendam, R. H., Camacho, V., Stone, A. P., Barrachina, M. N., Branfield, S. L., Carminita, E., Becker, I. C., Lee, D. H., Walsey, E., Payne, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.08.652525

PAK1 inhibition synergistically enhances the anti-tumor efficacy of PARP inhibitors in ovarian cancers

Li, C., Li, X., Gao, M., Deng, M., Li, Y., & Lou, Z. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101887

Additional file 2 of Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine

Tong, Z., Yan, C., Dong, Y.-A., Yao, M., Zhang, H., Liu, L., Zheng, Y., Zhao, P., Wang, Y., Fang, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12986286

Additional file 4 of Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine

Tong, Z., Yan, C., Dong, Y.-A., Yao, M., Zhang, H., Liu, L., Zheng, Y., Zhao, P., Wang, Y., Fang, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12986292

Additional file 5 of Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine

Tong, Z., Yan, C., Dong, Y.-A., Yao, M., Zhang, H., Liu, L., Zheng, Y., Zhao, P., Wang, Y., Fang, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12986295

Additional file 1 of High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

Verbeek, J. G. E., de Jong, V. M. T., Wijnja, H. M., Jager, A., Linn, S. C., Retèl, V. P., & van Harten, W. H. (2024) · Figshare · doi:10.6084/m9.figshare.26559875

Additional file 1 of Bleomycin induces senescence and repression of DNA repair via downregulation of Rad51

Chen, F., Zhao, W., Du, C., Chen, Z., Du, J., & Zhou, M. (2024) · Figshare · doi:10.6084/m9.figshare.25670075

Additional file 3 of High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

Verbeek, J. G. E., de Jong, V. M. T., Wijnja, H. M., Jager, A., Linn, S. C., Retèl, V. P., & van Harten, W. H. (2024) · Figshare · doi:10.6084/m9.figshare.26559881

Additional file 3 of Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine

Tong, Z., Yan, C., Dong, Y.-A., Yao, M., Zhang, H., Liu, L., Zheng, Y., Zhao, P., Wang, Y., Fang, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12986289

Additional file 1 of Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine

Tong, Z., Yan, C., Dong, Y.-A., Yao, M., Zhang, H., Liu, L., Zheng, Y., Zhao, P., Wang, Y., Fang, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12986280

Additional file 7 of Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine

Tong, Z., Yan, C., Dong, Y.-A., Yao, M., Zhang, H., Liu, L., Zheng, Y., Zhao, P., Wang, Y., Fang, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12986301

Additional file 2 of High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

Verbeek, J. G. E., de Jong, V. M. T., Wijnja, H. M., Jager, A., Linn, S. C., Retèl, V. P., & van Harten, W. H. (2024) · Figshare · doi:10.6084/m9.figshare.26559878

A prognostic signature derived from ac4C-associated genes stratifies survival and tumor immune microenvironment in cutaneous melanoma

Jin, Q., Jiang, N., Chen, G., Zhu, J., Niu, H., Han, Y., Li, C., Wang, S., & Liu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1727135

Insights on molecular mechanisms of chemoresistance in cervical cancer

Elangovan, M., Jain, S. M., Rafi, S. T. M., Thakkar, N., Ramachandran, I., Pathak, S., & Banerjee, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-22352-5.00015-6

Pharmacogenomic and High-Throughput Data Analysis to Overcome Triple Negative Breast Cancers Drug Resistance

Sadacca, B. (2017) · theses.fr (ABES) · doi:10.70675/86d0b41azfb6bz44bdz9f35zf24452ba9c6a

Role of tumor-surrounding adipocytes in breast cancer chemoresistance : molecular mechanisms and regulation by obesity

Li, X. (2017) · theses.fr (ABES) · doi:10.70675/da8b934bzce1ez4e46z905cz2e106c99db52

Implication du métabolisme de la sérotonine dans les cancers du sein triple négatifs et perspectives cliniques

Pinheiro, A. M. (2019) · theses.fr (ABES) · doi:10.70675/e234e25ez93ddz48d8z94daz0ebd0e211314

DNA repair dysregulation from cancer driver to therapeutic target

Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051

DNA repair and the contribution to chemotherapy resistance

Nesic, K., Parker, P., Swisher, E. M., & Krais, J. J. (2025) · Genome Medicine · doi:10.1186/s13073-025-01488-8 · Cited by 57

Targeting DNA damage response in cancer therapy

Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 309

Targeting DNA damage response pathways in cancer

Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 890

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Liptay, M., Barbosa, J. S., & Rottenberg, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00670 · Cited by 30